Sign In
Buy ELDN
$3.81
-0.110 (-2.81%)
At Close: Jun 22, 2026
Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney Transplantation Transcript
Eledon Presents Long-Term Phase 2 BESTOW Results at ATC Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart
Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year?
10:41am, Tuesday, 16'th Jun 2026
Here is how Eledon Pharmaceuticals, Inc. (ELDN) and Galderma Group AG - Unsponsored ADR (GALDY) have performed compared to their sector so far this year.
– All 12 patients in study (100%) achieved insulin independence, producing their own insulin and no longer requiring exogenous insulin therapy to manage their T1D – All 12 patients also achieved a
IRVINE, Calif. , June 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (Nasdaq: ELDN) today announced that updated results from an investigator-initiated trial being conducted at t
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at ADA
Is BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year?
10:40am, Friday, 29'th May 2026
Here is how BillionToOne (BLLN) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to their sector so far this year.
IRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company will present new clinical data from its tegoprubart program
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
04:05pm, Wednesday, 13'th May 2026
100% insulin independence achieved in 10 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study FDA Orphan Drug designation granted to
ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL),– NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapi
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives $9.67 Average Target Price from Brokerages
03:32am, Monday, 30'th Mar 2026
Shares of Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN - Get Free Report) have been given an average rating of "Hold" by the five ratings firms that are currently covering the stock, Marketbeat.com repo
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
05:10pm, Thursday, 19'th Mar 2026
Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Presented 24-month follow-up data from Phase 1b l
Eledon Pharmaceuticals: Tegoprubart Continues To Shine As Immunosuppressive Alternative
01:47pm, Monday, 16'th Mar 2026
Eledon Pharmaceuticals remains a "Strong Buy" following positive phase 2 BESTOW results for tegoprubart in kidney transplant rejection prevention. Company's tegoprubart demonstrated non-inferiority to
IRVINE, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
07:00am, Monday, 09'th Mar 2026
Collaboration Integrates Stem-Cell-Derived Islets with Targeted Immune Modulation ZURICH, Switzerland, March 9, 2026 /PRNewswire/ -- NewcelX Ltd. ("NewcelX") (Nasdaq: NCEL), a clinical-stage company a
